OUR PARTNERS IN THE LEIBNIZ RESEARCH ALLIANCE „HEALTH TECHNOLOGIES“

Leibniz Institute of Photonic Technology Jena (Leibniz IPHT) Ferdinand-Braun-Institut − Leibniz Institute PREVENTION. for High Frequency Technology (FBH) DIAGNOSIS. Innovations for High Perfomance Microelectronics (IHP) THERAPY.

Leibniz-Center for Medicine and Biosciences, Research Center Borstel (FZB) LEIBNIZ HEALTH TECHNOLOGIES Leibniz Institute for Analytical Sciences (ISAS) Office: Leibniz Research Centre for Working Environment Philosophenweg 7 and Human Factors (IfADo) 07743 Jena

Leibniz Institute for Astrophysics Potsdam Address: (AIP, associated) PO Box 100 239 D-07702 Jena Leibniz Institute for Interactive Materials (DWI) Phone: 0049 3641 948 362 Leibniz Institute for Natural Product Research and Infection Biology − Hans Knöll Institute (HKI) Fax: 0049 3641 948 302 Leibniz Institute for New Materials (INM) [email protected] Leibniz Institute of Plasma Science www.leibniz-healthtech.de and Technology (INP) Speaker: Leibniz Institute for Polymer Research Dresden Prof. Dr. Jürgen Popp (IPF)

Leibniz Institute for Economic Research Halle (IWH)

Weierstrass Institute for Applied Analysis and Stochastics (WIAS)

Associated Industrial Partners: ▪ Biophotonics Diagnostics GmbH ▪ neoplas tools GmbH THE COMPETENCE AREAS OUR COMPETENCE AREAS BIOMARKERS OF THE RESEARCH ALLIANCE Objective parameters for The partners in the Leibniz Research Alliance successful individualized therapy ­“Health Technologies” have defined five interdisci- plinary competence areas as central research pillars, The scientists in the competence area ­“Biomarkers” all of which pursue a common goal: To apply results are exploring the early detection of common of fundamental research as quickly and efficiently as ­diseases such as dementia, cancer, myocardial User Benefit possible for use as medical technologies. infarction or stroke. For this they use biomarkers: These are objective parameters of the patient, INDUSTRY Acceptance of New Technologies POLITICS which are clearly related to disease stages − Economic, Social and Ethical Consequences ­comparable to a blood glucose test for diabetes. HEALTH CLINICS INSURANCES

VENTURE CAPITALISTS GOVERNMENT AGENCIES POINT-OF-CARE TECHNOLOGIES PLASMA MEDICINE MEDICAL ASSOCIATIONS Reliable diagnoses Preventive care and within minutes personalized medical treatment

Novel point-of-care procedures (PoC) should Artificially produced, so-called “cold” plasmas LEIBNIZ HEALTH TECHNOLOGIES ­facilitate a risk assessment of widespread diseases have attracted attention in the past few years for A research alliance of the within a few minutes − ideally for several diseases applications in medicine. The reason: They kill at the same time. The aim is to provide fast and microorganisms while sparing healthy tissue and Concrete technology solutions for urgent ­medical reliable diagnostics with easy-to-obtain samples (for allow a targeted stimulation of cell growth. Plas- questions − this is the main focus of the 14 ­member example saliva, urine or tear fluid). This is ­expected mas are therefore already used today for wound institutes of the research alliance Leibniz Health to save costs and provide the ­patient with a more healing and for the prevention of infections. The Technologies. gentle screening method. scientists in the competence area of plasma med- icine develop therapeutic approaches further and Together with industry partners they are pursuing explore new medical applications. the goal of improving medical care for patients. Through an interdisci­plinary approach prevention, diagnosis and ­therapy shall grow together and thus IMAGING METHODS BIOACTIVE INTERFACES increase the quality of life. The alliance combines Fast detection and Functional materials for competencies from various fields: From photonics precise disease control state-of-the-art medical technology and medicine to microelectronics and material research, to economic research and applied mathe- In this competence area, Leibniz researchers Whether hydrogels, organ replacement systems, or matics. ­In close coordination with industry, hospitals, ­concentrate on high-sensitivity optical technol- stents in blood vessels − ­modern medicine depends insurance companies and politicians the research ogies that allow, for example, surgical interven- on functional materials and surfaces. Thus, Leibniz alliance develops health care technologies that tions to be precisely monitored in real-time. The Health Technologies is investigating materials are brought to market along a seamless ­innovation combination of innovative microscopy techniques that can be integrated well into the ­organism and chain. In parallel, Leibniz Health ­Technologies with ­spectroscopic methods allows unique insights prevent colonization with germs.Leibniz scientists ­investigates the social and economic consequences into the ­three-­dimensional structure and chemical ­develop bio­active ­surfaces which stimulate cells, of new medical technologies in order to optimize composition of individual cells up to organs − even release active substances and regulate healing their usefulness for the user and to ­create broad without having to label the tissue beforehand. processes. social acceptance for new technologies.